Acadia Pharmaceuticals Inc (Acadia) discovers, develops and commercializes small molecule drugs for the treatment of central nervous system (CNS) disorders. The company operates its business in one segment which is the development and commercialization of innovative medicines.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Focused research and development activities (R&D) enabled the company to develop innovative products and a broad pipeline of potential new medicines to secure brand image. With its strong R&D efforts, the company has strong pipeline products pimavanserin being evaluated for the treatment of various indications which include Schizophrenia, and dementia-related psychosis (DRP). It also completed HARMONY relapse prevention study, a Phase III, randomized, double-blind, placebo-controlled study, evaluating the efficacy and safety of pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP) and during the fiscal year, the company filed its supplemental new drug application (sNDA). The pipeline product of the company includes ACP-204 in Phase I clinical trials for the treatment of Alzheimer’s disease psychosis, Antisense Oligonucleotide (ASO) in pre-clinical trials is being developed for the treatment of rare genetic neurodevelopmental diseases of CNS. In FY2022, the company spent US$361.5 million on its research and development activities, which as a percentage of revenue stood at 69.9%, and grew 51% YoY.